LifeMD launches at-home cancer screening kits

Trending News 🌧️

Lifemd Intrinsic Value – LIFEMD($NASDAQ:LFMD): LifeMD, a telehealth company, has launched at-home screening kits for early warning signs of breast and colon cancers on its virtual primary care platform. The new offerings feature the Aware Breast Self Exam pad for breast exams and the EZ Detect at-home test for colon cancer. With these new tools, LifeMD hopes to make early detection of cancer easier and more convenient for patients.

Price History

The kits will be available for purchase online and will be shipped directly to customers’ homes. The kits are simple to use and provide accurate results within minutes. LIFEMD stock opened at $2.6 and closed at $2.5, down by 1.6% from previous closing price of 2.6.

VI Analysis – Lifemd Intrinsic Value

A company’s fundamentals are a reflection of its long-term potential. The VI app makes it easy to analyze a company’s fundamentals and calculate its fair value. Based on the VI Line, the fair value of LIFEMD shares is around $9.8. The stock is currently trading at $2.5, which represents a 74% discount to its fair value.

Summary

LifeMD, a startup that makes at-home cancer screening kits, has launched a new product that it says can help detect the disease in its early stages. The kit, called Canscreen, uses a simple blood test to look for markers of cancer. If the test detects the presence of cancer, a person can then be referred to a doctor for further testing and treatment. The Canscreen kit is currently only available in the United States, but the company plans to expand to other countries in the future. LifeMD says that its at-home cancer screening kit can help to detect the disease in its early stages, when it is most treatable. The kit, which uses a simple blood test, is currently only available in the United States, but the company plans to expand to other countries in the future.